about
Structure of human glycolate oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1,2,3-thiadiazolePurification and characterization of recombinant human liver glycolate oxidase.Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies.Successful prediction of substrate-binding pocket in SLC17 transporter sialin.Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.Clinical or ATPase domain mutations in ABCD4 disrupt the interaction between the vitamin B12-trafficking proteins ABCD4 and LMBD1.Ctr9, a Protein in the Transcription Complex Paf1, Regulates Dopamine Transporter Activity at the Plasma Membrane.Characterization of a Human Point Mutation of VGLUT3 (p.A211V) in the Rodent Brain Suggests a Nonuniform Distribution of the Transporter in Synaptic Vesicles.Spectral and 3D model studies of the interaction of orphan human cytochrome P450 2U1 with substrates and ligands.Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays.[Stimulating Type I interferon response with small molecules: revival of an old idea].Rose Bengal analogs and vesicular glutamate transporters (VGLUTs).Substituted thiazolamide coupled to a redox delivery system: a new gamma-secretase inhibitor with enhanced pharmacokinetic profile.Enhanced delivery of gamma-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy.Structural and Functional Characterization of the Interaction of Snapin with the Dopamine Transporter: Differential Modulation of Psychostimulant Actions.CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56.Membrane-bound human orphan cytochrome P450 2U1: Sequence singularities, construction of a full 3D model, and substrate docking.1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.[CXCR4, master regulator of innate immune responses?]Design, synthesis and biological evaluation of small-azo-dyes as potent Vesicular Glutamate Transporters inhibitors.5'-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: synthesis, biological evaluation and molecular modeling.Identification of Primary Natural Killer Cell Modulators by Chemical Library Screening with a Luciferase-Based Functional AssaySynthesis and biological activity of N-substituted spiro[benzoxazepine-piperidine] Aβ-peptide production inhibitorsSynthesis and anti-HIV properties of new hydroxyquinoline–polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strainsSimple Coupling Reaction between Amino Acids and Weakly Nucleophilic Heteroaromatic AminesReverse Immunology Approach to Define a New HIV-gp41-Neutralizing EpitopeBacterial Transferase MraY, a Source of Inspiration towards New AntibioticsAntidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depressionRegulation of IRE1 RNase activity by the Ribonuclease inhibitor 1 (RNH1)Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibitionLSP5-2157 a new inhibitor of vesicular glutamate transportersDestabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategyPseudomonas aeruginosa Lipoxygenase LoxA Contributes to Lung Infection by Altering the Host Immune Lipid Signaling
P50
Q24649940-6F0F2C7B-7050-4270-ACEB-996CAD6804D1Q34658480-B3C21CDD-BEA7-4CD7-BF08-9CD0EA3ECAF5Q35598600-A88CF26D-02AD-414D-B00F-066D9A6A5C8BQ35879473-39B31118-6BAD-4219-BD91-D53D25E1F90DQ37642643-2520212C-CE76-4DCD-B015-A8CB12B1625BQ38701568-C2FF58ED-1B2E-4B2E-BBFD-BA82989965CDQ38866802-C3CD35CC-4F39-4BC3-9FBB-354B2F1A8C23Q38896987-99E64181-6068-4240-931B-E122277DA7C0Q39561278-59FE3B2C-81AF-431E-BAEA-7E1AA51F89A0Q40258820-91089620-61B5-4DE6-BFF8-03D5A523A8EBQ40932056-62EA0931-BC8A-47D0-A7FA-B181C5C050D3Q42937633-7EAEAA98-E149-4034-A622-4697ED17D0A5Q45259689-46113945-C31E-4CAE-A32C-CE464C1A13AAQ46565353-61252BF0-F483-4FBB-A46E-D2819FC921BCQ47622230-1B3AAE53-24A2-4ACA-B844-3EA1D9A47EFEQ47649753-9A03ED47-9663-41DF-A08E-443EFE365E9FQ48028466-4E51A210-703A-4222-886A-180261FEFD38Q48596573-234C6204-FBE8-41BE-92D2-F1D9EF2F3844Q49845982-7ADBA101-1EB0-4066-8437-8F5046444040Q50224069-ED8FA609-B3A6-4797-ABA2-A800726ED7ACQ53841671-1449656C-473F-407D-88CD-A14008150DF2Q56914208-F6D98BDA-00B3-4234-BCE9-684BB9B60134Q58087917-63D4542C-5EE6-4255-A797-B6667CF7B920Q58087969-08DC284E-7C74-4A92-ADC4-64CF958815F5Q58088090-ADA13DCC-AB12-421F-A39F-04F8B426D124Q64057733-68A127A0-B480-474D-9AD9-58D6DA0023F2Q88223794-9F91BDF1-31A8-4C14-9AA4-A81FEC21665FQ90754624-5C421C2D-3778-45C2-BAE4-5356AA7E5303Q90955514-82799598-958C-4956-8BD7-50CAE49D6385Q91327340-84A20B5E-FF56-4634-8515-D8ADAFBE26D4Q91773345-E9B826B0-1509-4445-9BA5-149A7F58DDA5Q91930483-ED8A7639-E264-4F65-81F7-865ADB567375Q93047506-7B20D5A2-D982-453A-BAF1-91C0D39AE04B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicolas Pietrancosta
@ast
Nicolas Pietrancosta
@en
Nicolas Pietrancosta
@es
Nicolas Pietrancosta
@nl
type
label
Nicolas Pietrancosta
@ast
Nicolas Pietrancosta
@en
Nicolas Pietrancosta
@es
Nicolas Pietrancosta
@nl
prefLabel
Nicolas Pietrancosta
@ast
Nicolas Pietrancosta
@en
Nicolas Pietrancosta
@es
Nicolas Pietrancosta
@nl
P106
P21
P31
P496
0000-0002-9934-7818